NCT02466815View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Healthy
Interventions
DRUG

JNJ-42756493 Current Clinical Formulation (G-018)

JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

DRUG

JNJ-42756493 Prototype Formulation I (G-025)

JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

DRUG

JNJ-42756493 Prototype Formulation II (G-025)

JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02466815 - A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets | Biotech Hunter | Biotech Hunter